Evidence map›Paper›PMID 33225632›Full record

ArticleAdvanced healthcare materials2021

Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists.

Dinh Chuong Nguyen, Daniel Shae, Hayden M Pagendarm, Kyle W Becker, Mohamed Wehbe, Kameron V Kilchrist, Lucinda E Pastora, Christian R Palmer, Pedro Seber, Plamen P Christov and 2 more

Open access · greenAbstract read
In one paragraph

Article in Advanced healthcare materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Mn-based cGAS-STING activation for tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023
    Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Dinh Chuong NguyenDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Daniel ShaeDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Hayden M PagendarmDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Kyle W BeckerDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.ORCID 0000-0003-1627-2724
Mohamed WehbeDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Kameron V KilchristDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Lucinda E PastoraDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Christian R PalmerDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Pedro SeberDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Plamen P ChristovVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, 37232, USA.
Craig L DuvallDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
John T WilsonDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, 37235, USA.ORCID 0000-0002-9144-2634
Vanderbilt University · US

Funding

Integrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9M
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer ImmunotherapyR01CA245134 · NCI · VANDERBILT UNIVERSITY · PI WILSON, JOHN TANNER · 2020 to 2025
$1.8M
CIHRNCI NIH HHS R01 CA245134NIDDK NIH HHS T32 DK101003
6 · The paper itself

Abstract

Cyclic dinucleotide (CDN) agonists of stimulator of interferon genes (STING) hold great therapeutic potential, but their activity is hindered by poor drug-like properties that restrict cytosolic bioavailability. Here, this challenge is addressed through the synthesis and evaluation of a novel series of PEGMA-co-DEAEMA-co-BMA copolymers with pH-responsive, membrane-destabilizing activity to enhance intracellular delivery of the CDN, cGAMP. Copolymers are synthesized with PEGMA of two different molecular weights (300 and 950 Da) and over a range of PEG mass fraction and polymer molecular weight, and relationships between copolymer structure, self-assembly, endosomal escape, and cGAMP activity are elucidated. A subset of polymers that self-assembled into 50-800 nm nanoparticles is identified, which can be loaded with cGAMP via a simple mixing strategy, resulting in significantly enhanced immunostimulatory activity. Increased cGAMP activity is found to be highly correlated with the capacity of carriers to enhance intracellular CDN uptake and to promote endosomal destabilization, findings that establish efficient cytosolic delivery as a criterion for CDN carriers. Additionally, it is demonstrated that a lead CDN carrier formulation can enhance STING activation in vivo in a model of intratumoral immunotherapy. Collectively, these investigations demonstrate the utility of PEGMA-co-DEAEMA-co-BMA copolymers as carriers for CDNs and potentially other cytosolically-acting drug cargo.

Indexed as

Membrane ProteinsNanoparticlesImmunotherapyPolyelectrolytesPolymersMembrane ProteinsPolyelectrolytesPolymersendosomal escapegraft copolymerspolymer nanoparticlesself-assembling nanoparticlesstimulator of interferon genes (STING)

Identifiers

PMID33225632
PMCPMC7856189
OpenAlexW3108022909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.